Litcius/Paper detail

Mercaptobenzimidazole-Based 1,3-Thaizolidin-4-ones as Antidiabetic Agents: Synthesis, In Vitro α-Glucosidase Inhibition Activity, and Molecular Docking Studies

Sher Ali Khan, Mumtaz Ali, Abdul Latif, Manzoor Ahmad, Ajmal Khan, Ahmed Al‐Harrasi

2022ACS Omega15 citationsDOIOpen Access PDF

Abstract

In this research work, we have focused our efforts to synthesize a series of 2-mercaptobenzimidazole-based 1,3-thiazolidin-4-ones (5–24) following a multistep reaction strategy and characterization of the synthesized derivatives with the help of various spectroscopic techniques. To find the antidiabetic potentials of the synthesized compounds (5–24), in vitro alpha-glucosidase inhibitory activity was performed using acarbose (IC50 = 873 ± 1.2 μM) as the reference standard. The results of the antidiabetic assay were very encouraging because compounds 5, 8, and 14 showed excellent inhibitions with IC50 values of 5.22 ± 0.14, 5.69 ± 0.10, and 10.20 ± 0.12 μM, respectively. The experimental results of anti-alpha-glucosidase activity prompted us to investigate and propose a possible mechanism of how the active molecules will interact with the target enzyme. For this purpose, molecular docking with the AutoDock Vina (an open-source and reliable docking platform) gave us an insight into the binding interactions of the active compounds to different amino acid residues of the enzyme.

Topics & Concepts

In vitroDocking (animal)ChemistryCombinatorial chemistryPharmacologyStereochemistryBiochemistryMedicineNursingSynthesis and biological activityClick Chemistry and ApplicationsEnzyme Catalysis and Immobilization
Mercaptobenzimidazole-Based 1,3-Thaizolidin-4-ones as Antidiabetic Agents: Synthesis, In Vitro α-Glucosidase Inhibition Activity, and Molecular Docking Studies | Litcius